Transdermal selegiline in HIV-associated cognitive impairment: Pilot, placebo-controlled study

Ned Sacktor, G. Schifitto, M. P. McDermott, K. Marder, J. C. McArthur, K. Kieburtz

Research output: Contribution to journalArticlepeer-review

Abstract

The authors conducted a pilot randomized, double-blind, placebo- controlled clinical trial of the transdermal administration of selegiline in HIV+ patients to obtain preliminary data to assess its safety, tolerability, and impact on HIV-associated cognitive impairment. Both selegiline and placebo were well tolerated with few adverse events. Improvements favoring the selegiline group were suggested on single tests of verbal memory and motor/psychomotor performance, warranting a larger study.

Original languageEnglish (US)
Pages (from-to)233-235
Number of pages3
JournalNeurology
Volume54
Issue number1
DOIs
StatePublished - Jan 11 2000

Keywords

  • Cognitive impairment
  • HIV
  • Selegiline

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Transdermal selegiline in HIV-associated cognitive impairment: Pilot, placebo-controlled study'. Together they form a unique fingerprint.

Cite this